ORY 4001
Alternative Names: ORY-4001Latest Information Update: 23 Jun 2023
Price :
$50 *
At a glance
- Originator Oryzon
- Class Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Charcot-Marie-Tooth disease
Most Recent Events
- 21 Jun 2023 Pharmacodynamics data from a preclinical study in Charcot-Marie-Tooth disease and Amyotrophic lateral sclerosis released by Oryzon Genomics
- 15 Mar 2023 Preclinical trials in Amyotrophic lateral sclerosis in Spain(unspecified route)
- 15 Mar 2023 Preclinical trials in Charcot-Marie-Tooth disease in Spain(unspecified route)